Luke Evnin Sells 24,678 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 24,678 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $0.61, for a total value of $15,053.58. Following the completion of the sale, the director directly owned 2,368,849 shares of the company’s stock, valued at approximately $1,444,997.89. The trade was a 1.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.57, for a total value of $33,618.60.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.62, for a total transaction of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total transaction of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $22,448.16.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL opened at $0.57 on Wednesday. The stock has a 50 day simple moving average of $0.87 and a 200 day simple moving average of $1.24. The stock has a market cap of $27.74 million, a P/E ratio of -0.35 and a beta of 0.77. Werewolf Therapeutics, Inc. has a 1-year low of $0.53 and a 1-year high of $2.38. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. Research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Institutional Trading of Werewolf Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of HOWL. Quadrature Capital Ltd acquired a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at approximately $28,000. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics in the 2nd quarter valued at approximately $48,000. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics in the first quarter valued at approximately $79,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics during the second quarter worth $92,000. Finally, Bridgeway Capital Management LLC increased its holdings in shares of Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after buying an additional 62,414 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Bank of America decreased their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective on the stock. in a research note on Friday, December 19th. Citizens Jmp cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. HC Wainwright reduced their target price on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Finally, Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.